Centre for Precision Psychiatry - Quebec
The Centre for Precision Psychiatry (CPPQ) platform called Solutions for Psychiatric AI Research & Knowledge (SPARK) offers unique value by combining comprehensive clinical and biological data, enabling researchers to study the complex interactions driving psychiatric disorders. Its transdiagnostic design allows for research beyond traditional categorical diagnoses, and the extended 10-year follow-up period provides insights into long-term clinical outcomes that are not available in existing datasets.
The CPPQ dataset is designed to support a wide range of research, with a particular focus on AI models that enhance individualized diagnosis and treatment.
The platform core objectives include:
* Identifying data-driven diagnostic groups that share clinical and biological profiles.
* Determining the biomarkers, symptoms, and lifestyle factors predictive of disease progression.
* Developing algorithms that predict individual treatment efficacy.
Overview
- Acronym
- SPARK-CPPQ
- Website
- SPARK-CPPQ
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 2022 -
- General Information on Follow Up (profile, frequency)
-
After baseline, participants are seen at year 2, 5 and 10 years. Data on Psychiatric patients is also collected every six months.
- Recruitment Target
-
- Individuals
- Number of Participants
- 150
- Number of Participants with Biological Samples
- 150
- Supplementary information about number of participants
-
The study aims to recruit 1000 participants.
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Access request procedure: https://www.cppquebec.ca/access Information: https://www.cppquebec.ca/data
- On the study website : https://www.cppquebec.ca
- By contacting the study representative: Research Associate Sophie Blais-Michaud (RI-MUHC)
Sector of research
| Possible Access to Data | Possible Access to Biosamples | |
| Investigators from the public sector | ||
| Investigators from the private sector | ||
| Investigators from not-for-profit organization |
The research proposed must be presented by an academic investigator. Private research groups will require an academic principal investigator be associated with the project.
Transfer
| Possible Access to Data | Possible Access to Biosamples | |
| Can leave the study facility | ||
| Can leave the country |
a Material/Data Transfer Agreement (MDTA) is required prior to releasing the material/data. This document defines the way that the data will be used, who will have access to the data, how the data will be stored, and stipulates that researchers will not attempt to determine the identity of any participants] (e.g. anonymization, encryption, double coding, etc.
Cost
| Possible Access to Data | Variable Cost |
| Possible Access to Biosamples | Variable Cost |
The CPPQ will provide cost-free access to renewable data (clinical, cognitive, lifestyle, neuroimaging, and results of biological analyses including genetics, transcriptomics, etc.) for academic research groups. Research groups from industry will need to pay for access to this renewable data. In contrast, a fee will be associated with access to nonrenewable biological material for research groups from both academic and industry. The CPPQ will specify the cost to the research teams from both academia and industry when approving access to material/data from the CPPQ. All fees for academic researchers will be based on cost recovery and will not derive profit for the CPPQ.
Cost reduction for co-analyses
| Possible Access to Data | |
| Possible Access to Biosamples |
Depend on the context, would be assessed by the Access committee.
Supplementary Information
The CPPQ platform offers unique value by combining comprehensive clinical and biological data, enabling researchers to study the complex interactions driving psychiatric disorders. Its transdiagnostic design allows for research beyond traditional categorical diagnoses, and the extended 10-year follow-up period provides insights into long-term clinical outcomes that are not available in existing datasets.
Timeline
Populations
SPARK-CPPQ - Transdiagnostic Psychiatric
The population is composed of psychiatric patients who were diagnosed with either major depressive disorder, bipolar disorder, anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), personality disorder, schizophrenia, substance-related disorder, or gender dysphoria.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
65
- Countries
-
- Canada
- Canadian Provinces
-
- Quebec
- Health Status
-
- Participants with intellectual disabilities, neurocognitive disorders (e.g., dementia, Alzheimer’s disease, Parkinson’s disease), neurobiological diseases (e.g., multiple sclerosis, epilepsy), or diseases that significantly impact endocrine function (e.g., Cushing's disease, Hashimoto’s disease) are excluded.
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are recruited from two psychiatric hospitals, the Douglas Institute and the Montreal General Hospital, on a voluntary basis.
Sample Size
- Number of Participants
- 141
- Number of Participants with Biological Samples
- 141
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SPARK-CPPQ - Baseline |
|
|
2022 (January) | 2032 |
| 1 | SPARK-CPPQ - 6 months follow-up |
|
2022 (July) | 2032 | |
| 2 | SPARK-CPPQ - 12 months follow-up |
|
2023 (January) | 2032 | |
| 3 | SPARK-CPPQ - 18 months follow-up |
|
2023 (July) | 2032 | |
| 4 | SPARK-CPPQ - 2 years follow-up |
|
|
2024 | 2032 |
| 5 | SPARK-CPPQ - 30 months follow-up |
|
2024 (July) | 2032 | |
| 6 | SPARK-CPPQ - 36 months follow-up |
|
2025 (January) | 2032 | |
| 7 | SPARK-CPPQ - 42 months follow-up |
|
2025 (July) | 2032 | |
| 8 | SPARK-CPPQ - 48 months follow-up |
|
2026 (January) | 2032 | |
| 9 | SPARK-CPPQ - 54 months follow-up |
|
2026 (July) | 2032 | |
| 10 | SPARK-CPPQ - 5 years follow-up |
|
|
2027 | 2035 |
| 11 | SPARK-CPPQ - 66 months follow-up |
|
2027 (July) | 2032 | |
| 12 | SPARK-CPPQ - 72 months follow-up |
|
2028 (January) | 2032 | |
| 13 | SPARK-CPPQ - 78 months follow-up |
|
2028 (July) | 2032 | |
| 14 | SPARK-CPPQ - 84 months follow-up |
|
2029 (January) | 2032 | |
| 15 | SPARK-CPPQ - 90 months follow-up |
|
2029 (July) | 2032 | |
| 16 | SPARK-CPPQ - 96 months follow-up |
|
2030 (January) | 2032 | |
| 17 | SPARK-CPPQ - 102 months follow-up |
|
2030 (July) | 2032 | |
| 18 | SPARK-CPPQ - 108 months follow-up |
|
2031 (January) | 2032 | |
| 19 | SPARK-CPPQ - 114 months follow-up |
|
2031 (July) | 2032 | |
| 20 | SPARK-CPPQ - 10 years follow-up |
|
|
2032 | 2032 |
SPARK-CPPQ - Healthy Controls
The population is composed of healthy individuals.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
65
- Countries
-
- Canada
- Canadian Provinces
-
- Quebec
Sources of Recruitment
- General Population
-
- Volunteer enrolment
- Supplementary Information
-
Participants were recruited through social media advertisements and by distributing pamphlets to current patients, who then shared them with their relatives.
Sample Size
- Number of Participants
- 9
- Number of Participants with Biological Samples
- 9
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SPARK-CPPQ - Baseline |
|
|
2022 | 2032 |
| 4 | SPARK-CPPQ - 2 year follow-up |
|
|
2024 | 2032 |
| 10 | SPARK-CPPQ - 5 years follow-ups |
|
|
2027 | 2032 |
| 20 | SPARK-CPPQ - 10 years follow-up |
|
|
2032 | 2032 |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2025-07-21T11:57:40.906